Pharmaceuticals, Biotechnology and Life Sciences
BioNTech SE (Nasdaq: BNTX, “BioNTech”) has announced that it has taken a next step to improve vaccine supply in Africa.…
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd.,…
miDiagnostics, a POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for…
The startup company Novel Concepts Medical has announced that its novel plant-based treatment has resulted in successfully inhibiting the COVID-19…
AOP Orphan Pharmaceuticals announced that on Monday February 14, 2022 the German Federal Court of Justice decided on PEC’s challenge…
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate…
Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of…
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today…
AstraZeneca has reported increase of revenue of 41% (38 at CER) to $37,417 million in results for Q4 and full year 2021 released on Thursday. This includes revenue from COVID-19 vaccine of $3,981 million. The increase of revenue has been driven by five medicines: Tagrisso ($5bn+), Farxiga ($3bn+), Lynparza ($2bn+), Calquence ($1bn+) and Fasenra ($1bn+).
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sanofi’s…